IPN60300 consists of an antibody targeting ITGA2.Escugen EZWi Fit™ Platform Innovative Linker-PayloadComposed, it is expected to demonstrate superior efficacy over existing standard treatment regimens across various tumor indications, while maintaining a favorable safety profile. Preclinical studies have confirmed that IPN60300 can specifically and with high affinity bind to the ITGA2 target, which is highly expressed in multiple tumors, enabling efficient endocytosis of the exatecan payload. Further preclinical tumor model data show that the product exhibits dose-dependent antitumor activity, high enrichment in tumor tissues, excellent pharmacokinetics, and good tolerability in non-human primates, holding the potential to become a first-in-class therapy and improve clinical outcomes.

IPN60300 The preclinical research data validated Escugen.EZWi‑Fit™The Safety and Effectiveness of Platform Technology. Looking ForwardIPN60300 Clinical manifestations further validate the core competitiveness of Escugen's biotechnology platform, highlighting Chinese innovation. ADC A Solid Force Empowering Global Cancer Treatment with Technology, Helping More Patients Access Better Treatment Options.

Reading 546

Escugen ADC Pipeline Layout